Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96BI3

UPID:
APH1A_HUMAN

ALTERNATIVE NAMES:
Aph-1alpha; Presenilin-stabilization factor

ALTERNATIVE UPACC:
Q96BI3; B4DQK0; Q5TB22; Q5TB23; Q969R6; Q9BVG0; Q9Y386

BACKGROUND:
The Gamma-secretase subunit APH-1A, known alternatively as Aph-1alpha and Presenilin-stabilization factor, is a non-catalytic yet indispensable part of the gamma-secretase complex. This complex is responsible for the intramembrane cleavage of several crucial proteins, including Notch receptors and the amyloid-beta precursor protein (APP), thereby influencing key cellular signaling cascades. APH-1A's role is critical for the assembly and stability of the gamma-secretase complex, which in turn affects Notch and Wnt signaling and the regulation of cytosolic CTNNB1 levels.

THERAPEUTIC SIGNIFICANCE:
The strategic importance of Gamma-secretase subunit APH-1A in the regulation of vital cellular processes underscores its potential as a therapeutic target. By elucidating its function, new pathways for the treatment of diseases related to aberrant signaling pathways may be discovered.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.